remdesivir (Q28209496)

From Wikidata
Jump to navigation Jump to search
chemical compound and antiviral drug
  • GS-5734
  • 2-ethylbutyl (2S)-2-({[(2R,3S,4R,5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxyoxolan-2-yl]methoxy-phenoxyphosphoryl}amino)propanoate
  • Veklury
edit
Language Label Description Also known as
default for all languages
No label defined
    English
    remdesivir
    chemical compound and antiviral drug
    • GS-5734
    • 2-ethylbutyl (2S)-2-({[(2R,3S,4R,5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxyoxolan-2-yl]methoxy-phenoxyphosphoryl}amino)propanoate
    • Veklury

    Statements

    0 references
    Remdesivir.svg
    512 × 432; 11 KB
    0 references
    602.2253987099999 dalton
    0 references
    C₂₇H₃₅N₆O₈P
    0 references
    Nc3ncnn2c3ccc2C(C#N)(C1O)OC(C1O)CO[P](=O)(NC(C)C(=O)OCC(CC)CC)Oc4ccccc4
    0 references
    CCC(CC)COC(=O)[C@H](C)N[P@](=O)(OC[C@@H]1[C@H]([C@H]([C@](O1)(C#N)C2=CC=C3N2N=CN=C3N)O)O)OC4=CC=CC=C4
    0 references
    1 reference
    22 January 2022
    The antiviral remdesivir should not be used as treatment for hospitalized Covid-19 patients, the World Health Organization said Thursday, only a month after the Food and Drug Administration approved the drug to treat patients over age 12 who are hospitalized with Covid-19. (English)
    1 reference
    22 January 2022
    Although remdesivir performed well in preclinical studies, it did not meet efficacy endpoints in a randomized trial conducted during an Ebola outbreak. (English)
    1 reference
    FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links. (English)
    2 references
    22 January 2022
    WHO has issued a conditional recommendation against the use of remdesivir in hospitalized patients, regardless of disease severity, as there is currently no evidence that remdesivir improves survival and other outcomes in these patients. (English)
    22 January 2022
    However, the clinical efficacy of remdesivir for COVID-19 remains contentious, as several trials have not found statistically significant differences in either time to clinical improvement or mortality between remdesivir-treated and control groups. (English)
    1 reference
    22 January 2022
    Although remdesivir performed well in preclinical studies, it did not meet efficacy endpoints in a randomized trial conducted during an Ebola outbreak. (English)
    Remdesivir
    0 references

    Identifiers

    0 references
    0 references
    EMEA/H/C/005622
    0 references
    0 references
    0 references
     
    edit
      edit
      edit
        edit
          edit
            edit
              edit
                edit